Success Story: Approved in Just 5 Days! A Formulation Scientist Secures EB-1B Success with Premium Processing and Our Expert Guidance
Client’s Testimonial:
"I would like to sincerely thank the entire team for their outstanding work in securing approval of my EB-1B petition. Throughout the process, I had an excellent experience working with the attorneys. They were highly professional, knowledgeable, and responsive, consistently providing clear and accurate answers to all of my questions and concerns.”
On June 3rd, 2026, we received another EB-1B (Outstanding Professors and Researchers) approval for a Formulation Scientist in the Field of Biological Engineering (Approval Notice).
General Field: Biological Engineering
Position at the Time of Case Filing: Formulation Scientist
Country of Origin: India
State of Residence at the Time of Filing: New Jersey
Approval Notice Date: June 3rd, 2026
Processing Time: 5 days (Premium Processing Requested)
Case Summary:
We are pleased to share that the client’s I-140 EB-1B petition was approved in just 5 days after being filed directly with premium processing. The client is a biological engineering researcher whose work focuses on novel drug delivery systems in pharmaceutics, particularly for chronic rhinosinusitis, sialorrhea in pediatric and neurological patients, and cancer. The client is currently employed as a senior formulation scientist, where the client leads formulation development, optimization, and upscaling activities to advance drug products toward clinical evaluation.
Research Contributions in Drug Delivery and Biological Engineering
The petition demonstrated that the client’s work addresses important biomedical challenges by improving the efficacy, safety, and precision of therapeutic delivery. The client’s research includes sustained-release and targeted-delivery formulations designed to minimize systemic toxicity while maximizing therapeutic effect. We highlighted the client’s work on systemic and intranasal drug carriers for chronic sinus inflammation, controlled salivary gland drug formulations for sialorrhea, and polymeric nanoparticle-based chemotherapeutic systems designed to deliver drugs more precisely to tumor sites while sparing healthy tissue.
A Record of International Recognition
The client’s scholarly record included 8 peer-reviewed journal articles, with 4 first- or co-first-authored articles, 6 conference abstracts, with 4 first-authored abstracts, 1 book chapter, and 1 U.S. patent. The client’s work had also received 188 citations according to Google Scholar. In the petition, we did not present these numbers as automatically sufficient. Instead, we explained that the citation record reflected independent reliance on the client’s findings by other researchers working in drug delivery, nanomedicine, biofuel production, and targeted therapeutic systems.
Peer Review and Funding Support
The petition also emphasized that the client had completed at least 32 peer reviews, showing that journals in the field trusted the client’s expertise to evaluate the work of other researchers. We further highlighted evidence that the client’s research had been supported by major funding sources, including the National Institute of Allergy and Infectious Diseases, the National Center for Advancing Translational Sciences, and the National Institutes of Health. This funding evidence helped reinforce the scientific and public-health importance of the client’s research areas.
How We Demonstrated the Client’s Significance
To demonstrate the client’s significance, we organized the petition around both objective evidence and real research impact. We explained how the client’s work on chronic rhinosinusitis advanced nanoscale drug delivery and improved understanding of drug retention and localized treatment. We also highlighted the client’s cancer-related drug delivery research, which developed tumor-targeting approaches intended to improve chemotherapy precision and reduce treatment-related side effects. Additionally, the petition discussed the client’s well-recognized work developing a cost-effective catalytic pyrolysis process using red mud to convert invasive pinyon-juniper biomass into premium-quality biofuel, showing the breadth and originality of the client’s contributions.
Expert Endorsements
The case was supported by 8 recommendation letters from experts in the field, including independent experts familiar with the client’s work through its published influence. One expert noted that: “When his achievements are taken into account with his peer review responsibilities, there is no doubt that [Client’s] efforts are beneficial to both the United States and global research communities.”
EB-1B Approval and Outlook
By presenting the client’s research achievements as a cohesive record of original contribution, independent reliance, peer trust, and continued practical relevance, we demonstrated that the client met the requirements for classification as an outstanding researcher. We congratulate the client on this I-140 EB-1B approval and wish the client continued success in advancing biological engineering and drug delivery research in the United States.